Chemotherapy-Induced Central Retinal Artery Occlusion in Gestational Trophoblastic Neoplasia: Case Report.
central retinal artery occlusion
chemotherapy
cisplatin
gestational trophoblastic neoplasia
thromboembolism
Journal
International medical case reports journal
ISSN: 1179-142X
Titre abrégé: Int Med Case Rep J
Pays: New Zealand
ID NLM: 101566269
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
06
2020
accepted:
11
08
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
epublish
Résumé
The use of anticancer chemotherapy (ACC) has resulted in longer patient survival but has also increased drug-related adverse effects. A 22-year-old female receiving cisplatin-based intravenous chemotherapy for high risk variant of gestational trophoblastic neoplasia (GTN) presented with complaints of sudden painless loss of vision in her right eye for a duration of 4 hours. Ocular findings were suggestive of central retinal artery occlusion (CRAO). After exclusion of other potential aetiological risk factors, the patient was diagnosed with CRAO associated with cisplatin. Cancer patients are prone to thromboembolic events (TEE) not only due to primary disease but also due to underlying comorbidities and treatment modalities. The high incidence of TEE in patients under cisplatin therapy mandates a high degree of suspicion among the treating physicians. This rare possibility of irreversible visual toxicity should also be considered among the patients under cisplatin chemotherapy.
Identifiants
pubmed: 32982483
doi: 10.2147/IMCRJ.S266456
pii: 266456
pmc: PMC7501951
doi:
Types de publication
Case Reports
Langues
eng
Pagination
431-435Informations de copyright
© 2020 Khadka et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Neurol India. 2009 Jul-Aug;57(4):505-7
pubmed: 19770564
Br J Clin Pract. 1995 Jan-Feb;49(1):50-1
pubmed: 7742194
Cancer. 1992 Dec 1;70(11):2699-702
pubmed: 1384952
Cancer. 1993 Jul 15;72(2):587-93
pubmed: 8319192
Surv Ophthalmol. 2006 Jan-Feb;51(1):19-40
pubmed: 16414359
J Clin Oncol. 1997 Jul;15(7):2636-43
pubmed: 9215835
Oncology. 1985;42(5):296-300
pubmed: 3875817
N Engl J Med. 2003 Jul 10;349(2):109-11
pubmed: 12853582
Curr Opin Ophthalmol. 2000 Dec;11(6):462-7
pubmed: 11141642
Thromb Res. 2006;118(5):555-68
pubmed: 16388837
J Oncol Pharm Pract. 2019 Jun;25(4):969-971
pubmed: 29486639
J Clin Oncol. 2000 May;18(10):2169-78
pubmed: 10811682
Ophthalmology. 1983 Jan;90(1):1-3
pubmed: 6828303
Cancer. 2005 Mar 1;103(5):994-9
pubmed: 15666321
Am J Ophthalmol. 2006 Jan;141(1):196-7
pubmed: 16387001
Chemother Res Pract. 2011;2011:806256
pubmed: 22312558
J Clin Oncol. 2011 Sep 1;29(25):3466-73
pubmed: 21810688
Int Ophthalmol. 2011 Oct;31(5):429-32
pubmed: 22109828
Pharmacotherapy. 2002 Sep;22(9):1200-4
pubmed: 12222560
Cancer Ther. 2003;1:47-61
pubmed: 18185852
Arch Intern Med. 2000 Mar 27;160(6):809-15
pubmed: 10737280
Nat Clin Pract Neurol. 2008 Jul;4(7):376-83
pubmed: 18542123
Pharm Pract (Granada). 2006 Apr;4(2):55-9
pubmed: 25247000
Eur J Ophthalmol. 2010 Nov-Dec;20(6):1042-6
pubmed: 20544682
Am J Ophthalmol. 2005 Sep;140(3):376-91
pubmed: 16138997
J Clin Oncol. 2012 Dec 10;30(35):4416-26
pubmed: 23150697